HIV Once a Week Combination Medication

HIV-1 infection is a life-threatening and serious disease of major public health significance, with approximately 39 million people with HIV worldwide and approximately 29.8 million taking antiretroviral treatment. Standard of care for the treatment of HIV-1 infection involves the use of a combination of ARV drugs to suppress viral replication to below detectable limits, increase CD4 T-cell counts, and delay disease progression.

The purpose of this research study is to see if switching a single tablet of islatravir combined with lenacapavir once a week is safe, tolerable, and effective to use for the treatment of HIV infection compared to taking Biktarvy OR your current HIV medications every day.

The first period of this study will last approximately 2 years, and you will visit the clinic at least 11 times. If you continue your participation in the open-label period, it may last until the FDA approves the medication.

A few qualifications to participate are: 

• HIV-1 positive adults
• Biktarvy for at least 6 months prior to the first visit OR a standard-of-care combination HIV medication

Qualified participants will: 

• See a physician at no cost
• Receive medication and labs at no cost
• Receive compensation for time and travel